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Abstract
Autoinflammatory diseases (AIDs) were first described as clinical disorders characterized by recurrent episodes of seemingly
unprovoked sterile inflammation. In the past few years, the identification of novel AIDs expanded their phenotypes toward more
complex clinical pictures associating vasculopathy, autoimmunity, or immunodeficiency. Herein, we describe two unrelated patients
suffering since the neonatal period from a complex disease mainly characterized by severe sterile inflammation, recurrent bacterial
infections, and marked humoral immunodeficiency. Whole-exome sequencing detected a novel, de novo heterozygous PLCG2
variant in each patient (p.Ala708Pro and p.Leu845_Leu848del). A clear enhanced PLCγ2 activity for both variants was demon-
strated by both ex vivo calcium responses of the patient’s B cells to IgM stimulation and in vitro assessment of PLC activity. These
data supported the autoinflammation and PLCγ2-associated antibody deficiency and immune dysregulation (APLAID) diagnosis in
both patients. Immunological evaluation revealed a severe decrease of immunoglobulins and B cells, especially class-switched
memory B cells, with normal T and NK cell counts. Analysis of bone marrow of one patient revealed a reduced immature B cell
fraction compared with controls. Additional investigations showed that both PLCG2 variants activate the NLRP3-inflammasome
through the alternative pathway instead of the canonical pathway. Collectively, the evidences here shown expandAPLAID diversity
toward more severe phenotypes than previously reported including dominantly inherited agammaglobulinemia, add novel data
about its genetic basis, and implicate the alternative NLRP3-inflammasome activation pathway in the basis of sterile inflammation.
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Introduction
Autoinflammatory diseases (AIDs) constitute a specific group of
primary immunodeficiency diseases (PID) characterized by re-
current episodes of systemic sterile inflammation mainly medi-
ated by cells of innate immunity [1]. At present, around 30 dif-
ferent monogenic AIDs have been molecularly elucidated, with
some of the novel ones also displaying features of dysregulatedB
cell response either as circulating autoantibodies or as reduced
antibody production [2–5]. The extremely rare, dominantly
inherited PLCγ2-associated antibody deficiency and immune
dysregulation (PLAID) and autoinflammation and PLCγ2-
associated antibody deficiency and immune dysregulation
(APLAID) may be included among those rare monogenic
AIDs combining sterile inflammation and humoral
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immunodeficiency. Both diseases are linked to hypermorphic,
pathogenic variants in the PLCG2 gene encoding the key signal
transduction enzyme PLCγ2. They are clinically characterized
by early-onset skin inflammation and recurrent infections. In
addition, patients with APLAID often develop ocular and lung
inflammation, enterocolitis, and interstitial pneumonitis but un-
like PLAID, they do not present with cold urticaria or autoim-
munity [6–9]. However, because only a fewAPLAID cases have
been characterized so far, it is not clear to what extent their
clinical manifestations could differ or overlap with other immune
disorders. Similarly, the range of genetic changes (in PLCG2 or
in genes regulating associated signal transduction pathways) and
their impact on immune cell functions have not been defined.
In the present study we describe two unrelated patients with
early-onset severe skin and eye inflammation, and recurrent
bacterial infections secondary to antibody deficiency. Further
genetic and functional studies are consistent with APLAID
and consolidate and expand the key features and underpinning
molecular mechanisms for this diagnosis.
Patients and Methods
The ethics committees of Hospital Sant Joan de Déu, Hospital
Universitari Vall d’Hebron and Hospital Clínic, all in
Barcelona (Spain), approved the study.Written informed con-
sent for participation in the study was obtained from patients’
parents. Blood samples from patients and unaffected relatives
were collected for molecular studies, which were performed in
accordance with the Declaration of Helsinki.
Flow Cytometry Studies
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll gradient (Fresenius-Kabi Norge, Norway) and stained for
cell surface markers using fluorochrome-conjugated antibodies
(Supplementary Table S1). Samples were acquired using a
FACSCanto II cytometer (BDBiosciences, USA), and data were
analyzed with CellQuest software (BD Biosciences, USA).
Genetic Analyses
DNA samples were extracted from peripheral blood using a
QIAmp DNA Blood Mini Kit (Qiagen, Germany). Libraries
were prepared using TruSight One kit (Illumina, USA) in
Family 1 and SureSelect Human All exon V2 kit (Agilent
Technologies, USA) in Family 2 following manufacturer’s in-
structions. Paired-end sequencing was performed on an
Illumina Genome Analyzer II platform (Illumina, USA).
Reads were mapped against the human reference genome
hg19 using the BWA software and analyzed with the GATK
Unified Genotyper v2.8. Amplicon-based deep sequencing of
specific exons of the PLCG2 gene (RefSeq NM_002661.3)
was performed as previously described to evaluate parental
gene mosaicism [10]. For Sanger sequencing, specific exons
of the PLCG2 gene were amplified by in house–designed PCR
(primers listed in Supplementary Table S2), purified with
Illustra ExoStar 1-Step kit (GEHealthcare, USA), bidirectional
sequenced using ABI BigDye® Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, USA) and run on an
automated ABI 3730XL analyzer (Applied Biosystems, USA).
Analyses of Ca2+ Flux in B Cells and Measurements of
Phosphoslipase-C Activity
Intracellular Ca2+ flux was measured by flow cytometry after
labeling with FLUO-3 AM (Invitrogen, USA) as previously
described with slight modifications [6].
For the measurements of phosphoslipase-C (PLC) activity,
COS-7 cells were cultured inDMEM (Sigma-Aldrich, USA) con-
taining 10% (v/v) FBS and 2.5 mM glutamine (growth media).
Cells were grown as a monolayer at 37 °C in 5% CO2. COS-7
cellswere seeded into 96-well plates at a density of 7500 cells/well
in 0.1 mL of growth media and incubated overnight. Fresh media
was applied and the cells transfectedwith plasmidDNAat 100 ng/
well that had been diluted in 5 μL jetPRIME® buffer and 0.2 μL
jetPRIME® (Polyplus Transfection, France) that was prepared as
instructed by the manufacturer. The DNA concentration was kept
constant by adding empty plasmid. For the PLCγ2 expression
plasmids, the full-length ORF of human PLCG2 was cloned into
the vector pTriEx4 using Gateway technology (Thermo Fisher).
Mutations and deletions were prepared using the site-directed mu-
tagenesis kit (Agilent) following manufacturer’s instructions. The
ORFs of all constructs were fully sequenced prior to a Maxiprep
being performed to generate the plasmid DNA for transfection.
Each PLCγ2 construct was transfected at 4 concentrations in trip-
licate as outlined in the figures. Twenty-four hours post-transfec-
tion, the media was removed and replaced with growth media
without FBS but containing 0.25% (w/v) fatty acid free BSA.
The COS-7 cells were then incubated for further 24 h.
Subsequently, the media was replaced with growthmedia without
FBS but containing 50 mM LiCl with and without 100 ng/mL
EGF and incubated for further 1 h. The media was aspirated and
replaced by 25 μL of stimulation buffer (20 mM HEPES.OH,
2 mM CaCl2, 1 mM MgCl2, 8.4 mM KCl, 292 mM NaCl,
11 mM glucose and 100 mM LiCl, pH 7.4) followed by 25 μL
of lysis buffer (50 mMHEPES.OH, 0.8 M KF, 0.2% (w/v) BSA
and 1% (v/v) Triton-X-100, pH 7.0). The cells were lysed for
30 min at room temperature on an orbital shaker. Seven microli-
ters of the cell lysate was pipetted in duplicate into a white 384-
well plate (Greiner Bio-One GmbH, Austria) followed by 1.6 μL
of IP1-d2 (Cisbio, France). After 5 min, 1.6 μL of anti-IP1-
Cryptate (Cisbio, France) was added and the plate sealed and
incubated at room temperature for 1 h. The plate was read on a
PHERAstar (BMG Labtech, Germany) plate reader in HTRF
mode, and the data converted to IP1 concentration using a standard
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curve generated following manufacturer’s instructions. Data for
themeasured PLCactivity represent the standard error of themean
of transfections performed in triplicate.
Quantities of expressed proteins weremeasured using aWES
Western Blotting system (Protein Simple, USA). For this, a
further 96-well plate was transfected identically to the plate used
in the IP1 assay described above. Forty-eight hours post-trans-
fection, the cells were washed once in ice-cold PBS and subse-
quently lysed in 20 μL RIPA buffer (Thermofisher, USA) con-
taining a protease and phosphatase inhibitor cocktail
(Thermofisher, USA). The cells were freeze-thawed at − 20 °C
and subsequently 4 μL of each well loaded on a WES Western
Blotting. Proteinswere detectedwith a 1:150 dilution of the anti-
PLCγ2 antibody sc5283 (Santa Cruz) and a 1:150 dilution of
the anti-β-actin antibody 13E5 (Cell Signaling Technology).
For the comparison of PLC activity of different PLCγ2 variants,
the expression levels were quantitated and points with the same
protein expression used, as previously described [11]. The dif-
ferences were confirmed using the 2 tailed t test.
Detection of Intracellular ASC Specking and Active
Caspase-1
PBMCs were treated with either nothing or E. coli LPS serotype
055:B5 (Sigma-Aldrich, USA; 1 μg/mL, 2 h at 37 °C). LPS-
primed PBMCs were then stimulated with either nothing, ATP
(3 mM), or nigericin (10 μM) for 30 min at 37 °C. Stimulated
PBMCs were fixed with 2% paraformaldehyde (Sigma-Aldrich,
USA) and stained for the detection of intracellular ASC specks by
TOFIE as previously described [12], using the rabbit polyclonal
antibody anti-ASC (N-15)-R (Santa Cruz Biotechnology, USA).
For active caspase-1 detection, PBMCs were incubated for
1 h with FLICA660 reagent (ImmunoChemistry Technologies,
USA) and fixed following manufacturer recommendations.
Monocytes were detected with the APC-vio770-conjugated
anti-human CD33 antibody (Miltenyi Biotec, Germany) and
with the APC-Cy7-conjugated anti-human CD14 antibody
(TONBO Biosciences, USA). Stained cells were acquired on a
FACSCanto cytometer (BD Biosciences, USA). Cytokines
were measured in cell supernatants using a custom bead-based
multiplex Luminex immunoassay (eBioscience, USA). Heat
maps representing cytokine expression profiles were created
using Morpheus software (Broad Institute, Cambridge, USA).
Results
Clinical Description
Family 1
Patient 1 has been first described in 2007 [13] and is now a 16-
year-old girl. She was born from healthy parents at 40 weeks
of gestation by cesarean section due to loss of fetal wellbeing
(pedigree in Fig. 1a). The main features of her disease includ-
ed early-onset severe cutaneous and eye inflammation and
recurrent respiratory infections (Table 1).
Skin lesions appeared as early as the first day of life
as numerous papulo-vesicular lesions, which became
generalized during the following days requiring admis-
sion into pediatric intensive care unit. These lesions have
been nearly continuously present, with exacerbations,
occasionally hemorrhagic and complicated with infec-
tions, ulcerated lesions, and ulcerative granulomata
(Fig. 2a). In recent years, large areas of cutis laxa and
hyperpigmentation were detected (Fig. 2b). At 2.5 years
of age, bilateral conjunctivitis, corneal erosions, and
nodules appeared (Fig. 2c, d).
The absence of circulating immunoglobulins was de-
tected during the first year of life (Table 2). Intravenous
immunoglobulin (IVIG) replacement therapy (IVIGs;
400 mg/kg q3w) was then started and has been main-
tained until present. Despite this treatment, multiple infec-
tions were detected (cutaneous infections, acute gastroen-
teritis, periodontitis, herpetic stomatitis, bronchitis, and
pneumonia). At 4 years of age, multiple central bronchi-
ectases were detected on a CT scan (Fig. 2e), which sub-
sequently progressed and provoked recurrent episodes of
acute hemoptysis that required urgent embolization. As
consequence of these lesions, the medium right lung lobe
was surgically excised at the age of 13 years.
The patient received multiple treatments including antibiotics,
retinoids, corticosteroids, etanercept (25mg q1w for 5 years), and
anakinra (100 mg q1d for 1.5 years). With the use of etanercept
and anakinra, a partial control of skin inflammation was detected,
with no improvement of ocular manifestations or immune de-
fects. By contrast, a marked decrease of plasma C-reactive pro-
tein (CRP) was detected with etanercept (mean 6.86 mg/L; range
0.08–21-8) and anakinra (mean 0.10 mg/L; range 0.05–0.16)
compared with periods in which these treatments were not ad-
ministered (mean 13.32 mg/L; range 1.3–31.63).
Family 2
Patient 2 is a 9-year-old boy born from healthy parents
(pedigree in Fig. 1a). Skin manifestations started during
the first week of life as multiple erythematous macules,
papules, and large plaques, mainly located at arms, abdo-
men, and thighs (Table 1). These lesions recurred with no
periodicity, sometimes presenting as urticaria-like, vesicu-
lar or pustular lesions (Fig. 2f) or ulcerated or exudative
plaques. Infections, minor traumas, vaccinations, and heat
were identified as triggering or worsening factors. They
were successfully treated with oral or topical corticoste-
roids (1 mg/kg q1d), and partially with dapsone (1 mg/kg
q1d), and they healed leaving focal, wrinkled-appearing
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patches of cutis laxa and residual hyperpigmentation (Fig.
2g). Ocular inflammatory manifestations have recently ap-
peared as bilateral red eye, corneal limbitis, and episcleritis
(Fig. 2h).
Infections started at the age of 2 months as recurrent,
mild viral bronchitis. Since the age of 4 years, recurrent
bacterial infections were detected, mainly at ear (> 10 ep-
isodes) and lung (4 pneumonias), leading to mild bronchi-
ectasis (Fig. 2e). All infections were successfully treated
with oral antibiotics, without hospitalization. IVIG re-
placement therapy (500 mg/kg q3w) was started in
January 2016, which resulted in a decrease of the frequen-
cy of respiratory infections and in a marked improvement
of patient’s health status.
Hematological and Immunological Parameters
Laboratory monitoring revealed increased inflammatory
markers (CRP, platelet count) and reduced hemoglobin in
both patients (Supplementary Fig. S1). Immunological tests
repeatedly revealed low-to-absent immunoglobulins and
marked decrease of B cells in both patients, with T and NK
cell counts repeatedly normal (Table 2). A comprehensive
analysis of circulating B cells revealed their near complete
absence in patient 1 and an overall decrease of all B cell
subpopulations, a decreased response to polysaccharide vac-
cination, and the absence of autoantibodies in patient 2
(Table 2 and Supplementary Table S3). Bone marrow aspira-
tion was once performed in patient 1, which revealed that B
Fig. 1 Familial pedigrees and features of PLCG2 variants. Panel a
Pedigrees of enrolled families. Black filled symbols represent affected
individuals, open symbols unaffected individuals, squares male
individuals and circles female individuals. Panels b, c Schemes of
filtering of the next-generation sequencing strategies used in the
enrolled families. Panel d Sanger sense chromatograms of the PLCG2
gene from patients (upper boxes) and from wild-type healthy subjects
(bottom boxes). Gray arrows indicate the PLCG2 variants detected in
the patients. Panel e Scheme of structural domains of phospholipase
Cγ2 protein. The already known APLAID-associated PLCG2
mutations are showed in red fonts, while the PLCG2 variants described
in the present work are displayed in blue fonts. Panel fMultiple sequence
alignment of human phospholipase Cγ2 and sixteen orthologues. The
single asterisk represents the amino acid residue 708 of human
phospholipase Cγ2, while two asterisks indicate the amino acid
residues 845–848
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cell lineage represented 6.2% of total leukocytes and 28.4% of
total lymphocytes, with the presence of all B cell stages.
However, a reduction of the immature B cell stage compared
with healthy controls was detected (Supplementary Fig. S2).
Molecular Genetics
Genetic analyses identified rare candidate variants in both
patients (Fig. 1b, c shows candidate filtering strategies;
Supplementary Table S4 lists the gene variants detected in
patient 1). Assuming a dominant inheritance pattern for the
disease, patients only shared heterozygous variants at PLCG2
gene (p.Leu845_Leu848del in Family 1 and p.Ala708Pro in
Family 2) (Fig. 1d and Table 3). Additional investigations
confirmed that they were novel, de novo, and germline
PLCG2 variants (Supplementary Table S5). According to
the consensus joint recommendations of the American
College of Medical Genetics and Genomics and the
Association of Molecular Pathology [14], these two PLCG2
variants were classified as pathogenic on the basis of different
criteria including their de novo nature, their absence in healthy
controls, their location in regulatory domains and in conserved
residues of the protein (Fig. 1e–f), and the results of different
bioinformatics and functional analyses (Table 3).
Functional Characterization of PLCγ2 Variants
Analyses of Ca2+ flux in CD19+ cells after IgM crosslinking
and ionomycin stimulation were performed in both patients
using Fluo-3 flow cytometric assay. In patient 1, no firm
Fig. 2 Description of cutaneous,
pulmonary, and ocular
inflammatory manifestations in
patients.Panel aMultiple papules
and serosal and hemorrhagic
vesicles on the hands and palms
detected in patient 1 at the age of
4 years. Panel b Large areas of
cutis laxa in the abdominal region
detected in patient 1 at the age of
7 years. Panels c, d Ocular
inflammatory lesions including
intense bilateral conjunctivitis,
keratitis, episcleritis, and nodules
in the sclera detected over the
course of the disease in patient 1.
Panel e Bronchiectasis detected
in patient 1. Panel f Blistering
inflammatory cutaneous lesions
in the leg detected in patient 2 at
the age of 6 months. Panel g
Areas of cutis laxa detected in
patient 2 at the age of 6 years.
Panel h Ocular inflammatory
lesions including conjunctivitis
and corneal limbitis detected in
patient 2 at the age of 7 years
992 J Clin Immunol (2020) 40:987–1000
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conclusions were drawn from these analyses due to the nearly
complete absence of circulating B cells (data not shown). By
contrast, analyses performed in patient 2 revealed a signifi-
cantly higher release of Ca2+ into the cytosol of B cells after
IgM crosslinking stimulation than in cells from control sub-
jects, whereas no significant differences were observed after
ionomycin stimulation (Supplementary Fig. 3A-C).
Further analysis of novel APLAID variants was per-
formed in a standard PLC assay, similar to that previously
used to measure the activity of PLAID and APLAID var-
iants [6–8]. In this type of analysis, using model cell sys-
tems, the substrate is presented in native membranes and
the production of inositol phosphates measured under bas-
al or stimulated conditions. As shown in Fig. 3a, both
variants have higher PLC activity compared with the wild
type with the p.Ala708Pro substitution showing a greater
increase in basal and stimulated activities. When analyzed
in the context of CLL resistance to ibrutinib, p.Ala708Pro
mutation had a pronounced effect [15], consistent with
our observations.
NLRP3-Inflammasome Activation and Cytokine
Secretion
PBMCs from APLAID patients showed an increased pro-
duction of different cytokines after LPS treatment compared
with healthy controls, which was similar to that detected in
PBMCs from cryopyrin-associated periodic syndrome
(CAPS) patients. The upregulated cytokines included proin-
flammatory cytokines such as TNF-α and different members
of IL-1 family (IL-1α, IL-1β, IL-1Ra, IL-18) (Fig. 4a). The
increased release of IL-1 cytokines occurred simultaneously
to an increase of ASC speck formation and activation of
caspase-1 on LPS-treated monocytes from APLAID and
CAPS patients when compared with monocytes from
healthy individuals (Fig. 4b). IL-1β and IL-18 release from
APLAID patients’ PBMCs after LPS treatment was compa-
rable to that of CAPS patients (Fig. 4c). The release of IL-
1β and the activation of caspase-1 induced by LPS in
APLAID PBMCs were reduced when intracellular calcium
was chelated with BAPTA-AM or when the widely used
PLC inhibitor U73122 was used (Fig. 4d). Canonical acti-
vation of the NLRP3-inflammasome by adding ATP or
nigericin after LPS priming resulted in an equal formation
of intracellular ASC specks in monocytes and similar release
of IL-1β in samples from healthy donors, APLAID patients,
and CAPS patients (Fig. 4e). Collectively, these results sug-
gest an over-activation of the alternative NLRP3
inflammasome pathway in monocytes from APLAID pa-
tients, which could be enhanced by the elevated levels of
intracellular calcium associated with the increased activity of
mutated PLCγ2.Ta
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Discussion
The patients here described were initially suspected of suffering
from a rare disease combining humoral immunodeficiency and
inflammatory manifestations. Previous genetic studies did not
identify defects in different genes causing monogenic antibody
deficiencies or AIDs [1, 16]. Due to strong similarities, we
hypothesized that the patients’ disease might be a consequence
of defects in the same gene. Our further genetic studies revealed
that each patient carried a novel, de novo heterozygous PLCG2
pathogenic variant. Furthermore, our extensive characterization
of clinical manifestations, properties of immune cells, and
changes in function of the encoded enzyme, PLCγ2, support
a definitive diagnosis of PLCγ2-associated antibody deficiency
and immune dysregulation syndrome, designated as APLAID.
Previously, only 4 patients from three families have been
diagnosed with APLAID [7–9] and have been found to share
some of the manifestations with Ali5 and Ali14 mouse strains
that carry gain-of-function PLCG2mutations [17, 18]. Another
two families carrying the same PLCG2 variant in the C2 do-
main of the protein have been recently described during manu-
script reviewing [19]. The two unrelated patients described in
our study enable us to make more extensive comparisons and
highlight the key changes that characterize the human syn-
drome and parallels with the mouse models. These include
severe inflammatory lesions at skin, ocular, and joints mediated
by non-lymphoid hematopoietic cells and variable degree of
immunodeficiency. With regard to the immune defects, all
known APLAID patients exhibited variable degrees of B cell
lymphopenia and antibody deficiency, with no apparent impair-
ment of T and NK functions (Table 1). Patient 1 carrying the
p.Leu845_Leu848 PLCG2 deletion showed the complete ab-
sence of B cells and circulating immunoglobulins, an immune
phenotype compatible with a rare form of non-X-linked agam-
maglobulinemia [16] and quite similar to the immune pheno-
type of the APLAID patients carrying the missense
Fig. 3 PLC activity analyses. Panel a The effect of p.Ala708Pro and
p.Leu845_Leu848del variants on PLC activity was measured in
transfected COS-7 cells under basal conditions (basal) or after stimulation
by EGF (stimulated). Each data point represents the mean of triplicates and
error bars indicate standard error of the mean. Expression levels of PLCγ2,
corresponding to increasing concentrations of plasmids used for
transfection, were measured using WES (top, inset). Further evaluation of
the differences in PLC activities between the WT and variants was
performed for the points with an equal protein expression. Panel b
Position of p.Ala708 and p.Leu845-Leu848 segment (red arrows) is
mapped on the structure of cSH2 and spPH domain, respectively.
Positions of other mutations, reported for the main PLCγ1- and PLCγ2-
linked pathologies that map to the same domains, are labeled using single
letters and numbers corresponding to PLCγ2 sequence. Residues so far
found to be mutated only in PLCγ1 are shown in gray. Other residues
mutated in APLAID (p.Ser707 and p.Leu848) and Ali14 mice (p.Tyr495)
are indicated by orange arrows
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p.Leu848Pro PLCG2 variant [8, 9]. The humoral immunodefi-
ciency of this patient (patient 1) was clinically characterized by
severe and recurrent bacterial infections, structural lung lesions,
recurrent episodes of acute hemoptysis, and the requirement of
surgical lung lobe resection. To our knowledge, this patient
represents the severest APLAID patient described to date and
clearly expands the diversity of the immune deficiency of this
disease toward phenotypes compatible with dominantly
inherited agammaglobulinemia. Since allogeneic hematopoietic
stem cell transplantation has been proposed as a curative option
in severe PID [20, 21], a major unsolved question is whether
this particular patient would have benefited from this therapeu-
tic approach at a younger age, even with the causative genetic
defect not elucidated. With regard to patient 2 who carried the
missense p.Ala708Pro PLCG2 variant, his immunological phe-
notype (low IgM and B cell count and decreased circulating
class-switched memory B cells) could be classified as mild-to-
moderate and displayed marked similarities with the phenotype
of the first described APLAID family carrying the missense
p.Ser707Tyr PLCG2 variant [7]. The B cell disturbances ob-
served in patients with APLAID are variable ranging from pa-
tients displaying low circulating B cells to patients with absent
B cells. PLCG2 was proposed as a good candidate gene to
explain some B cell deficiencies in humans because the mouse
model of PLCγ2 deficiency showed a decrease of mature B cell
and a block in the pro-B cell differentiation [22]. However, the
human deficiency of PLCγ2 has not been yet described. By
contrast, monoallelicPLCG2mutations are associatedwith var-
iable humoral immune deficiency and immune dysregulation in
PLAID and APLAID syndromes [6–9]. The few available data
about the defects of the B cell lineage in APLAID patients do
not permit to drawn firm conclusions about the precise molec-
ular mechanisms underlying the humoral deficiency in these
patients. Considering the relevant role of PLCγ2 in multiple
signal transduction pathways in B cells and the gain-of-function
nature of PLCG2 variants detected in APLAID syndrome, a
mechanism that may explain the immune phenotype observed
and that should be further investigated is the deletion and/or
functional anergy of specific B cell progenitors due to enhanced
cellular signaling.
We were particularly interested in sterile inflammatory le-
sions and their molecular basis. From a clinical perspective, the
cutaneous manifestations were the most prominent in both of
our patients (patient 1 and 2) since the onset of their diseases as
have been also described for the other four published APLAID
patients [7–9]. These manifestations were initially vesicular and
blistering lesions that subsequently evolved to the destruction
of elastin fibers leading to large areas of cutis laxa in both
patients, a phenomenon also described in the APLAID patient
with the p.Leu848Pro PLCG2 variant [8]. Later in life both
patients also developed severe eye inflammation, mainly affect-
ing conjunctiva and episclera. The beneficial effect of topic
anakinra in the ocular lesions in PLAID [23] suggests the po-
tential combination of topical ocular treatments to the systemic
therapies that both patients are already receiving.
We have further investigated the molecular mechanisms
underlying sterile inflammation in APLAID. We found that
the novel PLCγ2 variants here identified were able to induce
activation of the NLRP3 inflammasome, with ASC aggrega-
tion, caspase-1 activation, and IL-1β and IL-18 release in
monocytes. Previous evidence suggested a potential connec-
tion between hypermorphic PLCG2 mutations and NLRP3-
inflammasome activation throughout the increase of intracel-
lular calcium [7, 16, 24, 25]. Consequently, it is possible that
in the patients described here, the sterile inflammation mani-
festations could be also linked to NLRP3-inflammasome. Our
results showed that canonical activation pathway of NLRP3-
inflammasome in patient’s monocytes did not result in an
increase of IL-1β release or ASC-specking as observed for
healthy monocytes. Therefore, the inflammasome pathway
that is potentiated in APLAID might be related to the alterna-
tive NLRP3 activation pathway, similar to that described in
human monocytes upon LPS activation [26], rather than the
canonical pathway that requires ATP or nigericin as second
stimuli after LPS priming [27].
Finally, our identification of two new pathogenic variants in
PLCG2 l i n k ed t o APLAID (p .A l a708P ro and
p.Leu845_Leu848) expands the range of genetic changes that
cause this syndrome. Consistent with previous studies [7–9],
we show that the new PLCG2 variants have higher PLC
Fig. 4 Involvement of NLRP3-inflammasome activation in sterile
inflammation. Panel a Heat map of cytokine analysis from peripheral
blood mononuclear cell (PBMCs) supernatants after LPS stimulation as
indicated (1 μg/mL, 2 h) isolated from healthy controls (n = 5), patients
with CAPS (heterozygous for p.Arg260Trp NLRP3 mutation; n = 2) or
APLAID carrying the heterozygous p.A708P (n = 1) or p.Leu845_
Leu848del (n = 1) PLCG2 variants. Representative of relative values of
minimum and maximum concentrations measured per cytokine. Panel b
Apoptosis-associated Speck-like protein containing a Caspase
recruitment domain (ASC) speck forming monocytes by flow
cytometry and active caspase-1 by YVAD-Fluorochrome Inhibitor of
Caspases (FLICA) staining on monocytes after LPS stimulation as
indicated (1 μg/mL, 2 h) isolated from healthy controls, patients with
CAPS, or patients with APLAID. Showed results are representative of
duplicate experiments. Panel c PBMCs IL-1β and IL-18 cytokine
production at baseline and after LPS stimulation as indicated (1 μg/mL,
2 h) in healthy controls, patients with CAPS, and patients with APLAID.
Showed results are representative of duplicate experiments. Panel d
PBMCs IL-1β and percentage of monocytes stained for active caspase-
1 by FLICA at baseline and after LPS stimulation (1 μg/mL, 2 h) in the
presence or absence of BAPTA-AM (20 μM) or U73122 (2.5 μM) as
indicated in APLAID patient 1 (p.Leu845_Leu848del PLCG2 variant)
and her healthy mother. Showed results are representative of experiments
performed only once due to limited availability of samples. Panel e
PBMCs IL-1β and ASC speck forming monocytes upon canonical
NLRP3 activation by LPS priming (1 μg/mL, 2 h) followed by 30-min
treatment with ATP (3 mM) or nigericin (10 μM) in healthy controls,
patients with CAPS, and patients with APLAID. Showed results are
representative of duplicate experiments. ND, not detected
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activity compared with the wild type. Interestingly,
p.Ala708Pro PLCG2 variant has been also discovered in
ibrutinib-resistant chronic lymphocytic leukemia (CLL) in the
form of somatic variant [28–30]. Two other somatic PLCG2
variants detected in resistant CLL, p.Ser707Tyr and
p.Asp993Gly, are also shared with immune disorders in
APLAID [7] and Ali5 mice [17], respectively. More broadly,
the new variants map to distinct regions in the cSH2 domain,
and spPH domain and its vicinity, the regions that appear to
harbor mutations across different PLCγ-linked pathologies
with higher frequencies (Fig. 3b). Therefore, the molecular
mechanisms that lead to an increase in PLC activity in diverse
pathologies could be similar. Considerable supporting evidence
is consistent with a model where PLCγ2 is kept in an inactive
state by extensive intramolecular interactions between the reg-
ulatory domains (including cSH2 and spPH domains) and the
PLC-core domains [11, 31]. Release of this autoinhibition by
physiological stimulation (via phosphorylation) or bymutations
represents an important step leading to an increase in PLC
activity. Therefore, our data showing that the novel variants
are hypermorphic and their position in the protein highlight
particular structural features within the regulatory array that
are the key regions involved in autoinhibition.
In conclusion, from the perspective of clinical practice,
the detection of a novel, de novo hypermorphic PLCG2
pathogenic variant in each of the two patients displaying
early-onset severe skin and eye inflammation and humoral
immunodeficiency supports their definitive diagnosis of
the extremely rare APLAID syndrome. Moreover, the pa-
tients’ immunological features expand the APLAID diver-
sity toward most severe phenotypes than previously de-
scribed including complete B cell depletion and agamma-
globulinemia inherited as a dominant trait, which should
be considered when evaluating patients with severe defi-
ciencies of antibody production.
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